TY  - BOOK
AU  - Sugarbaker, Paul H
TI  - After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye. [Review]
SN  - 0960-7404
PY  - 2022///
KW  - *Colorectal Neoplasms
KW  - *Hyperthermia, Induced
KW  - *Peritoneal Neoplasms
KW  - Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - Colorectal Neoplasms/dt [Drug Therapy]
KW  - Colorectal Neoplasms/pa [Pathology]
KW  - Combined Modality Therapy
KW  - Cytoreduction Surgical Procedures
KW  - Fluorouracil
KW  - Humans
KW  - Mitomycin/tu [Therapeutic Use]
KW  - Peritoneal Neoplasms/dt [Drug Therapy]
KW  - Peritoneal Neoplasms/sc [Secondary]
KW  - Washington Cancer Institute
KW  - Journal Article
KW  - Review
N2  - In the management of colorectal and appendiceal peritoneal metastases, intraperitoneal 5-fluorouracil (5-FU) has been used in 3 different ways. It has been used as part of an early postoperative intraperitoneal chemotherapy (EPIC) regimen along with EPIC mitomycin C. This EPIC mitomycin C plus EPIC 5-FU has been shown to be equivalent or inferior to HIPEC. Because it is more work intensive than HIPEC and not superior, its use should be abandoned if HIPEC is available. A second way to use intraperitoneal 5-FU is along with HIPEC. Several studies suggest a survival advantage for the combination of HIPEC with EPIC 5-FU. However, patient ineligibility for EPIC 5-FU in high-risk CRS is more likely the cause for the alleged survival advantage attributed to the combination. A third use of intraperitoneal 5-FU is long-term through a peritoneal access device. This plan for 5-FU use has shown favorable results in three randomized controlled studies. Normothermic intraperitoneal chemotherapy (NIPEC) with 5-FU should be considered as a regional chemotherapy component of a randomized trial for prevention or treatment of peritoneal metastases from colorectal or appendiceal cancer. Intravenous oxaliplatin combined with NIPEC 5-FU has been suggested as a bidirectional adjuvant regimen. Copyright © 2022 Elsevier Ltd. All rights reserved
UR  - https://dx.doi.org/10.1016/j.suronc.2022.101757
ER  -